Abstract
CRR9 monoclonal antibodies kill tumors & re-sensitize them to chemotherapy independently of oncogenic drivers, including KRas-driven, ovarian, lung & pancreatic tumors. We have a validated target, and established MOA & in vivo POC data.
Our novel CRR9-inhibiting human monoclonal antibodies:
- are stable, scalable, fully human IgG1 lead inhibitors
- specifically, target the most relevant CRR9 epitope & tumor tissues
- don’t have measurable toxicity
- hit one target, but multiple pathways
- kill as monotherapy & are synergistic with apoptosis-inducing agents with potential for combination (chemo, radiation, targeted, and immune) therapy
Website
Contact Information
MCW Office of Technology Development: https://www.mcw.edu/departments/technology-development
Name: Kevin Boggs, Ph.D., MBA
Title: Director
Phone: (414) 955-4381
Email: kpboggs@mcw.edu